22033-10-9 Usage
Uses
Used in Chemical Synthesis:
N-(2-Methoxyethyl)urea is utilized as a reagent in organic synthesis, contributing to the creation of a variety of chemical products due to its reactive properties.
Used in Pharmaceutical Production:
N-(2-METHOXYETHYL)UREA serves as a raw material in the manufacturing process of pharmaceuticals, playing a crucial role in the development of various medications.
Used in Pesticide Formulation:
N-(2-Methoxyethyl)urea is also employed in the production of pesticides, where it may enhance the effectiveness or stability of the final product.
Used as a Solvent:
Due to its solubility characteristics, N-(2-Methoxyethyl)urea is used as a solvent in different industrial processes, facilitating the dissolution of other substances for various applications.
Used in Other Chemical Industries:
Beyond the mentioned uses, N-(2-Methoxyethyl)urea finds application in other chemical industries, highlighting its versatility and importance in a range of practical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 22033-10-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,2,0,3 and 3 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 22033-10:
(7*2)+(6*2)+(5*0)+(4*3)+(3*3)+(2*1)+(1*0)=49
49 % 10 = 9
So 22033-10-9 is a valid CAS Registry Number.
InChI:InChI=1/C4H10N2O2/c1-8-3-2-6-4(5)7/h2-3H2,1H3,(H3,5,6,7)
22033-10-9Relevant articles and documents
TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS
-
Paragraph 0362-0366, (2022/01/12)
The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
Inhibitors of Herpes Simplex virus uracil-DNA glycosylase
-
, (2008/06/13)
The invention is directed to novel 6-aromatic substituted uracil compounds of formula I therapeutic compositions comprising the compounds, and methods of treating Herpes simplex virus Type I and Type II recurrent infections and Herpes simplex virus Type I and Type II encephalitis in humans using the compounds and/or therapeutic compositions.
6-anilinouracil-based inhibitors of bacillus subtilis DNA polymerase III: Antipolymerase and antimicrobial structure-activity relationships based on substitution at uracil N3
Tarantino Jr., Paul M.,Zhi, Chengxin,Gambino, Joseph J.,Wright, George E.,Brown, Neal C.
, p. 2035 - 2040 (2007/10/03)
6-Anilinouracils (6-AUs) are dGTP analogues which selectively inhibit the DNA polymerase III of Bacillus subtilis and other Gram-positive bacteria. To enhance the potential of the 6-AUs as antimicrobial agents, a structure- activity relationship was devel
